Abstract
GABA, acting via GABAA receptors, is well-accepted as the main inhibitory neurotransmitter of the mature brain, where it dampens neuronal excitability. The receptors properties have been studied extensively, yielding important information about its structure, pharmacology, and regulation that are summarized in this review. Several GABAergic drugs have been commonly used as anesthetics, sedatives, and anticonvulsants for decades. However, findings that GABA has critical functions in brain development, in particular during the late embryonic and neonatal period, raise worthwhile questions regarding the side effects of GABAergic drugs that may lead to long-term cognitive deficits. Here, we will review some of these drugs in parallel with the control of CNS development that GABA exerts via activation of GABAA receptors. This review aims to provide a basic science and clinical perspective on the function of GABA and related pharmaceuticals acting at GABAA receptors.
Keywords: GABA, anesthesia, epilepsy, neurogenesis, glutamate, proliferation, apoptosis, synaptic
CNS & Neurological Disorders - Drug Targets
Title: GABAA Receptors, Anesthetics and Anticonvulsants in Brain Development
Volume: 7 Issue: 2
Author(s): Oliver Henschel, Keith E. Gipson and Angelique Bordey
Affiliation:
Keywords: GABA, anesthesia, epilepsy, neurogenesis, glutamate, proliferation, apoptosis, synaptic
Abstract: GABA, acting via GABAA receptors, is well-accepted as the main inhibitory neurotransmitter of the mature brain, where it dampens neuronal excitability. The receptors properties have been studied extensively, yielding important information about its structure, pharmacology, and regulation that are summarized in this review. Several GABAergic drugs have been commonly used as anesthetics, sedatives, and anticonvulsants for decades. However, findings that GABA has critical functions in brain development, in particular during the late embryonic and neonatal period, raise worthwhile questions regarding the side effects of GABAergic drugs that may lead to long-term cognitive deficits. Here, we will review some of these drugs in parallel with the control of CNS development that GABA exerts via activation of GABAA receptors. This review aims to provide a basic science and clinical perspective on the function of GABA and related pharmaceuticals acting at GABAA receptors.
Export Options
About this article
Cite this article as:
Henschel Oliver, Gipson E. Keith and Bordey Angelique, GABAA Receptors, Anesthetics and Anticonvulsants in Brain Development, CNS & Neurological Disorders - Drug Targets 2008; 7 (2) . https://dx.doi.org/10.2174/187152708784083812
DOI https://dx.doi.org/10.2174/187152708784083812 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The DREAM of Pain Relief
Current Rheumatology Reviews Carbonic Anhydrase I and II Inhibition with Natural Products: Abrus precatorius
Current Enzyme Inhibition Somatostatin sst4 Ligands: Chemistry and Pharmacology
Mini-Reviews in Medicinal Chemistry Origin and Expansion of Trinucleotide Repeats and Neurological Disorders
Current Genomics AMPA Receptor Antagonists with Additional Mechanisms of Action: New Opportunities for Neuroprotective Drugs?
Current Pharmaceutical Design The Interleukin-1 System: An Attractive and Viable Therapeutic Target in Neurodegenerative Disease
Current Drug Targets - CNS & Neurological Disorders Monogenic Diabetes: Genetics and Relevance on Diabetes Mellitus Personalized Medicine
Current Diabetes Reviews Pharmacological Effects and Chemical Constituents of Bupleurum
Mini-Reviews in Medicinal Chemistry In Vivo MRI in Different Models of Experimental Epilepsy
Current Drug Targets Omega-3 Fatty Acids in the Management of Epilepsy
Current Topics in Medicinal Chemistry Association between <i>Toxoplasma gondii</i> Infection and Headache: A Systematic Review and Meta-Analysis
Infectious Disorders - Drug Targets Methods and Compositions for Amplification and Detection of microRNAs (miRNAs) and Noncoding RNAs (ncRNAs) Using the Signature Sequence Amplification Method (SSAM)
Recent Advances in DNA & Gene Sequences (Discontinued) Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations
Current Pharmaceutical Design Alzheimer’s Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function
Current Alzheimer Research GABAergic Drugs for the Treatment of Migraine
CNS & Neurological Disorders - Drug Targets Design, Synthesis and Antidepressant and Anticonvulsant Effect of 1-Alkoxy-1H-Benzo[d]-1,2,3-Triazole Derivatives
Letters in Drug Design & Discovery ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design The Need to Avoid the Routine Use of Episiotomy
Current Women`s Health Reviews Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued)